Biocon Ltd (BIOCON)

NSE · Healthcare · Pharmaceuticals & Biotechnology · Pharmaceuticals

₹351.80

As of 30 Oct 2026 close.

Facts from reported results and exchange filings. Not investment advice.

Share price

Prices load here as you scroll to them.

Last close ₹351.80 on 30 Oct 2026. The share price traded between ₹318.40 and ₹447.15 (intraday) over the last 12 months.

The closes as a table

DateClose

Key figures

1-year range (intraday)

Last close ₹351.80

Low ₹318.40High ₹447.15

Market cap₹57,316 crorelast close × shares
P/E104.7on reported profit, last four quarters, consolidated
Profit, last 12 months₹547 crto shareholders
Profit incl. minorities₹416 crlast 12 months
Return on equity1.4%year to Mar 2026
EBITDA margin21%year to Mar 2026
Debt to equity0.45year to Mar 2026
Net margin2.2%year to Mar 2026
Dividend yield0.14%last 12 months

Price trend

Revenue and profit

RevenueNet profit₹ crore
05,00010,00015,00020,000
YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue8,18411,17414,75615,26216,927
Net profit7726431,2981,429369
EBITDA margin22%22%22%21%21%
Borrowings5,14718,01916,27718,36215,434

₹ crore. Over three years, compounded: revenue grew 14.8% a year, net profit fell 16.9% a year.

Recent filings

Questions about Biocon Ltd

What is Biocon Ltd's market value?

Biocon Ltd's market value is ₹57,316 crore as of 30 Oct 2026 close: the last close times the shares in issue. Its P/E is 104.7, the last close over earnings per share for the last four reported quarters.

When are Biocon Ltd's next results?

Biocon Ltd's next results are listed for 4 Nov 2026 (the exchange's notice: Financial Results). Dates are as the company announced them, on the list of 30 Oct 2026.

Who are Biocon Ltd's largest named shareholders?

In the shareholding pattern for the quarter ended 30 Sep 2026, the largest named holders above 1% were: KIRAN MAZUMDAR-SHAW (promoter group) 29.73%; GLENTEC INTERNATIONAL (promoter group) 14.56%; SBI ESG EXCLUSIONARY STRATEGY FUND (public) 9.18%. Percentages are of all shares.

Go further with BIOCON

Free to start: test a trading idea on BIOCON's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.

Same industry

The largest companies in the same industry (Pharmaceuticals), by market value.

Browse companies

The companies before and after this one, A to Z, and the lists it is in.

How these figures are worked out

P/E 104.7 is the close over earnings per share, the profit that belongs to the company's shareholders (market cap divided by P/E: 547 crore for the last 12 months, shown above). The net profit including the share owned by minority shareholders of subsidiaries is 416 crore; market cap divided by that gives 137.8. The last 12 months are the four latest reported quarters, so their profit can differ from the newest year's in the table below.